Research Analysts Set Expectations for PLX Q1 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Protalix BioTherapeutics in a report released on Friday, May 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of $0.09 for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.12 EPS and Q4 2026 earnings at $0.14 EPS.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative return on equity of 30.89%.

Separately, Wall Street Zen cut Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th.

Protalix BioTherapeutics Trading Down 3.7%

NYSE PLX traded down $0.06 on Monday, hitting $1.56. 1,450,108 shares of the company traded hands, compared to its average volume of 541,989. The company has a market capitalization of $124.19 million, a price-to-earnings ratio of -12.00 and a beta of -0.05. The business's 50 day moving average price is $2.39 and its 200-day moving average price is $2.19. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $3.10.

Hedge Funds Weigh In On Protalix BioTherapeutics

Large investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Protalix BioTherapeutics during the 4th quarter valued at $35,000. Marshall Wace LLP purchased a new position in shares of Protalix BioTherapeutics during the 4th quarter valued at $192,000. Renaissance Technologies LLC lifted its position in shares of Protalix BioTherapeutics by 17.0% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock valued at $2,102,000 after acquiring an additional 162,100 shares in the last quarter. PFG Investments LLC purchased a new position in shares of Protalix BioTherapeutics in the fourth quarter valued at about $39,000. Finally, Prudential Financial Inc. purchased a new position in shares of Protalix BioTherapeutics in the fourth quarter valued at about $68,000. Hedge funds and other institutional investors own 16.53% of the company's stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.